5-碘-1H-苯并[d]咪唑-1-羧酸叔丁酯 | 705262-62-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 5-碘-1H-苯并[d]咪唑-1-羧酸叔丁酯
• 英文名称: 5-iodo-benzoimidazole-1-carboxylic acid tert-butyl ester
• 英文别名: tert-Butyl 5-iodo-1H-benzo[d]imidazole-1-carboxylate；tert-butyl 5-iodobenzimidazole-1-carboxylate
• CAS: 705262-62-0
• 化学式: C₁₂H₁₃IN₂O₂
• 分子量: 344.152
• InChiKey: JCLOZQWFPPQKMX-UHFFFAOYSA-N

物化性质

• 沸点：
  399.9±34.0 °C(Predicted)
• 密度：
  1.65±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  5-碘-1H-苯并[d]咪唑-1-羧酸叔丁酯 、 2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-3-boronic acid 在 四(三苯基膦)钯 、 碳酸氢钠 作用下， 以 二甲基亚砜 为溶剂， 反应 0.17h， 以56%的产率得到5-[2-(6-methyl-pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]-1H-benzoimidazole
  参考文献：
  名称：

  Dihydropyrrolopyrazole Transforming Growth Factor-β Type I Receptor Kinase Domain Inhibitors:  A Novel Benzimidazole Series with Selectivity versus Transforming Growth Factor-β Type II Receptor Kinase and Mixed Lineage Kinase-7

  摘要：

  Novel dihydropyrrolopyrazole-substituted benzimidazoles were synthesized and evaluated in vitro as inhibitors of transforming growth factor-beta type I receptor (TGF-beta RI), TGF-beta RII, and mixed lineage kinase-7 (MLK-7). These compounds were found to be potent TGF-beta RI inhibitors and selective versus TGF-beta RII and MLK-7 kinases. Benzimidazole derivative 8b was active in an in vivo target (TGF-beta RI) inhibition assay.

  DOI：

  10.1021/jm058209g
• 作为产物：
  描述：

  二碳酸二叔丁酯 、 5-碘苯并咪唑 在 碳酸氢钠 作用下， 以 甲醇 为溶剂， 反应 4.0h， 以88%的产率得到5-碘-1H-苯并[d]咪唑-1-羧酸叔丁酯
  参考文献：
  名称：

  Dihydropyrrolopyrazole Transforming Growth Factor-β Type I Receptor Kinase Domain Inhibitors:  A Novel Benzimidazole Series with Selectivity versus Transforming Growth Factor-β Type II Receptor Kinase and Mixed Lineage Kinase-7

  摘要：

  Novel dihydropyrrolopyrazole-substituted benzimidazoles were synthesized and evaluated in vitro as inhibitors of transforming growth factor-beta type I receptor (TGF-beta RI), TGF-beta RII, and mixed lineage kinase-7 (MLK-7). These compounds were found to be potent TGF-beta RI inhibitors and selective versus TGF-beta RII and MLK-7 kinases. Benzimidazole derivative 8b was active in an in vivo target (TGF-beta RI) inhibition assay.

  DOI：

  10.1021/jm058209g

文献信息

• [EN] NOVEL COMPOUNDS AS PHARMACEUTICAL AGENTS<br/>[FR] DERIVES PYRAZOLO CONDENSES
  申请人：LILLY CO ELI

  公开号：WO2004050659A1

  公开（公告）日：2004-06-17

  The current invention relates to compounds of the formula:(Ia) and the pharmaceutically acceptable salts thereof and their use as TGF-beta signal transduction inhibitors for treating cancer and other diseases in a patient in need thereof by administration of said compounds.

  目前的发明涉及以下式(Ia)的化合物及其药用盐，以及它们作为TGF-beta信号传导抑制剂用于治疗患有癌症和其他疾病的患者的用途，通过给予这些化合物进行治疗。
• Novel compounds as pharmaceutical agents
  申请人：Beight Wade Douglas

  公开号：US20060058295A1

  公开（公告）日：2006-03-16

  The current invention relates to compounds of the formula: (Ia) and the pharmaceutically acceptable salts thereof and their use as TGF-beta signal transduction inhibitors for treating cancer and other diseases in a patient in need thereof by administration of said compounds.

  本发明涉及以下化合物的公式：（Ia），以及其药学上可接受的盐，并通过给予该化合物的途径将其用作TGF-beta信号转导抑制剂，以治疗患有癌症和其他疾病的患者。
• US7405299B2
  申请人：——

  公开号：US7405299B2

  公开（公告）日：2008-07-29
• Dihydropyrrolopyrazole Transforming Growth Factor-β Type I Receptor Kinase Domain Inhibitors:  A Novel Benzimidazole Series with Selectivity versus Transforming Growth Factor-β Type II Receptor Kinase and Mixed Lineage Kinase-7
  作者：Hong-yu Li、Yan Wang、Charles R. Heap、Chi-Hsin R. King、Sreenivasa R. Mundla、Matthew Voss、David K. Clawson、Lei Yan、Robert M. Campbell、Bryan D. Anderson、Jill R. Wagner、Karen Britt、Ku X. Lu、William T. McMillen、Jonathan M. Yingling

  DOI：10.1021/jm058209g

  日期：2006.3.1

  Novel dihydropyrrolopyrazole-substituted benzimidazoles were synthesized and evaluated in vitro as inhibitors of transforming growth factor-beta type I receptor (TGF-beta RI), TGF-beta RII, and mixed lineage kinase-7 (MLK-7). These compounds were found to be potent TGF-beta RI inhibitors and selective versus TGF-beta RII and MLK-7 kinases. Benzimidazole derivative 8b was active in an in vivo target (TGF-beta RI) inhibition assay.